Skip to content

Cerebellar rTMS for Essential Tremor

Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02704793
Enrollment
23
Registered
2016-03-10
Start date
2016-04-30
Completion date
2018-05-31
Last updated
2018-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor

Brief summary

Essential tremor (ET) is a low-mortality, though truly burdensome and debilitating condition which is known to be the second most common movement disorder of the adult population only after restless legs syndrome. The prevalence of the disorder in all age groups has been estimated to be 0.9%. Repetitive transcranial magnetic stimulation (rTMS) is an almost safe technique which has been used in diagnosis and treatment of many neurologic and psychiatric conditions. Recent studies have shown that cerebellum has a significant role in development of ET and that rTMS could exert therapeutic effects on its motor symptoms. In this study researchers will recruit at least 30 subjects among patients visiting at the Specialty Clinic of Mashhad Medical University according to researchers exclusion and inclusion criteria and after signing a written informed consent, will randomly be assigned to either real or sham rTMS. On the real rTMS arm, patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days and sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS. Subject's ear will be protected with earplugs during both real and sham stimulations. After 2 months of follow-up, patients will undergo crossover and receive the other treatment as described above. Patients would be assessed using Fahn-Tolosa-Marin scale at the baseline and again on days 5, 12, and 30 after each real or sham treatment session by a blinded researcher. Data will be analysed by another researcher who is also blind.

Interventions

OTHERBilateral 1 Hz Cerebellar rTMS

900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.

OTHERSham (electrical stimulation)

900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.

Sponsors

Mashhad University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* having a diagnosis of essential tremor (ET) based on Movement Disorder Society criteria, involving at least one hand. * 18 years or above * cognitively eligible to give informed consent of participation in the trial.

Exclusion criteria

* Cardiac pace-maker or other implanted magnetic device or having other contraindications of performing a routine non-contrast MRI * skin defect at the occipital area preventing placement of a coil * Currently pregnant or plan for pregnancy in the next 6 months * History of seizure * Other comorbid medical conditions capable of producing or enhancing tremor * advanced cardiac, renal, hepatic or other disabling conditions making patient physical unable to participate in examination and receiving the intervention * Use of new drugs with potential effect on tremor

Design outcomes

Primary

MeasureTime frame
change in score of Fahn-Tolosa-Marin scaleat the baseline and on days 5, 12, and 30 after each real or sham treatment session.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026